Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update Life Science Investing
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update Biotech Investing
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Biotech Investing
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering Life Science Investing
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview Life Science Investing
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering Life Science Investing
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results Life Science Investing
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
